Gritstone Oncology
Gritstone Oncology is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Gritstone Oncology.
Gritstone Oncology is a company.
Key people at Gritstone Oncology.
Key people at Gritstone Oncology.
Gritstone bio (formerly Gritstone Oncology) is a clinical-stage biotechnology company developing next-generation immunotherapies, primarily personalized cancer vaccines targeting neoantigens to harness the immune system against tumors.[1][2][4] It focuses on oncology programs like GRANITE (individualized neoantigen vaccine for microsatellite-stable colorectal cancer, MSS-CRC, in Phase II/III with FDA fast-track) and SLATE (off-the-shelf vaccine for non-small cell lung cancer with KRAS mutations, in Phase II), while also pursuing infectious disease vaccines for COVID-19 and HIV.[3][6] The company serves cancer patients with hard-to-treat solid tumors, solving the problem of immune resistance by generating potent, durable responses even in immunologically "cold" tumors.[1][2][3] After filing for Chapter 11 in October 2024, it emerged leaner in April 2025, prioritizing R&D with maturing Phase 2 data showing improved progression-free survival (PFS) for GRANITE.[2][6]
Gritstone Oncology launched in October 2015 with a $102 million Series A financing co-led by Versant Ventures and The Column Group, alongside Clarus Ventures, Frazier Healthcare Partners, Redmile Group, Casdin Capital, and others.[4][5] Co-founders include Dr. Tim Chan and Dr. Naiyer Rizvi, who pioneered neoantigen work for lung cancer at Memorial Sloan Kettering; Prof. Jean-Charles Soria (lung cancer expert, Institut Gustave Roussy); Prof. Graham Lord (lymphocyte biology, King's College London); and Dr. Mark Cobbold (antigenic-peptide expert, Massachusetts General).[4] The idea emerged from breakthroughs in cancer genomics and immunotherapy, targeting tumor-specific neoantigens (TSNAs) initially for non-small cell lung cancer (NSCLC).[4] Early traction included a planned $80 million IPO in 2018 (backed by Lilly Ventures, GV, Bluebird Bio, raising $188 million total by then) and advancement of GRANITE into Phase 1/2 trials.[5] Headquartered in the San Francisco Bay Area (with operations in Cambridge, MA, and a recent partnership at MBC Biolabs incubator), it evolved under leaders like President & CEO Andrew Allen and scientific experts like Matthew Hawryluk.[1][3][4]
Gritstone rides the neoantigen immunotherapy wave, expanding beyond checkpoint inhibitors to address resistance in solid tumors, a key trend as immuno-oncology matures toward cures.[3][4] Timing aligns with maturing trial data (e.g., GRANITE's strengthening PFS in MSS-CRC, an underserved "cold" tumor market) and post-2025 restructuring enabling focused advancement amid biotech funding pressures.[2][6] Market forces like rising cancer incidence, demand for personalized medicine, and infectious disease needs (HIV/COVID vaccines) favor its platform, which de-risks expansion across tumors via shared tech.[3][6] It influences the ecosystem by validating neoantigen approaches, partnering with incubators like MBC Biolabs ($20B+ capital hub), and inspiring off-the-shelf scalability, potentially unlocking immunotherapy for millions.[1][6]
Gritstone's next 12-18 months hinge on GRANITE Phase II/III readouts and SLATE progression, with ongoing strategic funding/partnerships post-restructuring to sustain R&D.[3][6] Trends like AI-driven antigen discovery, combination therapies with checkpoint inhibitors, and infectious disease pivots will shape it, amplifying platform potential across oncology and beyond.[2][3] Its influence may evolve from distressed innovator to streamlined leader if trial momentum delivers, tying back to its core mission: pioneering immunotherapies that turn immune recognition into durable wins against tough cancers.[1][6]
